TY - JOUR
T1 - Suspected pharmacological interactions in a cancer patient during methadone maintenance
AU - Ferretti, Gianluigi
AU - Di Cosimo, Serena
AU - Ceribelli, Anna
AU - Milella, Michele
AU - Gelibter, Alain
AU - Cognetti, Francesco
PY - 2004
Y1 - 2004
N2 - A 50-year-old man with chemotherapy resistant stage IV bronchioalveolar lung carcinoma had been managed successfully with oral methadone for opioid addiction for more than 30 years. Fifty days before admission, gefitinib, an oral epidermal growth factor receptor inhibitor, was prescribed. At admission he was confused with persistent hypotension. He received oxygen, bronchodilators, dexamethasone, ranitidine, and phenobarbital. The fifth in-hospital day, after developing the overdose syndrome, methadone was stopped. When he subsequently presented symptoms of withdrawal, methadone was reintroduced, but he continued displaying tachypnea, until he died for respiratory failure. Physicians should pay careful attention to the clinical respiratory symptoms and radiographic findings of these patients, especially during the first months after starting gefitinib. Further research into specific gefitinib interactions with the P450 enzyme systems is encouraged.
AB - A 50-year-old man with chemotherapy resistant stage IV bronchioalveolar lung carcinoma had been managed successfully with oral methadone for opioid addiction for more than 30 years. Fifty days before admission, gefitinib, an oral epidermal growth factor receptor inhibitor, was prescribed. At admission he was confused with persistent hypotension. He received oxygen, bronchodilators, dexamethasone, ranitidine, and phenobarbital. The fifth in-hospital day, after developing the overdose syndrome, methadone was stopped. When he subsequently presented symptoms of withdrawal, methadone was reintroduced, but he continued displaying tachypnea, until he died for respiratory failure. Physicians should pay careful attention to the clinical respiratory symptoms and radiographic findings of these patients, especially during the first months after starting gefitinib. Further research into specific gefitinib interactions with the P450 enzyme systems is encouraged.
UR - http://www.scopus.com/inward/record.url?scp=2942602730&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2942602730&partnerID=8YFLogxK
U2 - 10.1097/00132576-200406000-00006
DO - 10.1097/00132576-200406000-00006
M3 - Article
AN - SCOPUS:2942602730
VL - 3
SP - 87
EP - 92
JO - Addictive Disorders and their Treatment
JF - Addictive Disorders and their Treatment
SN - 1531-5754
IS - 2
ER -